Endothelium activation in the anti-phospholipid syndrome

E. Raschi, C. Testoni, M. O. Borghi, S. Fineschi, P. L. Meroni

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Anti-phospholipid syndrome is an autoimmune systemic disease characterized by the persistent presence of anti-phospholipid antibodies and by the occurrence of thrombosis, fetal loss and thrombocytopenia. Anti-phospholipid antibodies are widely accepted as pathogenic antibodies mainly directed against the phospholipid-binding protein beta 2 glycoprotein I. Beta 2 glycoprotein I can be expressed on the endothelial cell membranes of different anatomical localizations and recognized by the autoantibodies. The antibody binding might induce an endothelial activation both in vitro and in vivo experimental models, that was suggested to represent one of the pathogenic mechanisms leading to the prothrombotic state of the syndrome. Beta 2 glycoprotein I endothelial adhesion was found to take place through the interaction of the cationic phospholipid binding site of the molecule with anionic endothelial structures and through annexin II, the endothelial cell receptor for tissue plasminogen activator. Anti-beta 2 glycoprotein I antibodies can directly activate the cells via NF-kB translocation and the signaling cascade triggered by toll like receptors. It has been suggested that beta 2 glycoprotein I might be associated with toll like receptors because of its molecular mimicry with bacterial structures, the natural ligands of toll like receptors. The binding of the antibodies is thought to cross-link beta 2 glycoprotein I and the toll like receptors, eventually switching their signaling pathway.

Original languageEnglish
Pages (from-to)282-286
Number of pages5
JournalBiomedicine and Pharmacotherapy
Volume57
Issue number7
DOIs
Publication statusPublished - Sep 1 2003

Fingerprint

beta 2-Glycoprotein I
Antiphospholipid Syndrome
Endothelium
Toll-Like Receptors
Phospholipids
Antibodies
Anti-Idiotypic Antibodies
Endothelial Cells
Annexin A2
Molecular Mimicry
Bacterial Structures
NF-kappa B
Tissue Plasminogen Activator
Thrombocytopenia
Autoantibodies
Autoimmune Diseases
Carrier Proteins
Thrombosis
Theoretical Models
Binding Sites

Keywords

  • Anti-phospholipid antibodies
  • Endothelial cells
  • Toll like receptors

ASJC Scopus subject areas

  • Pharmacology

Cite this

Endothelium activation in the anti-phospholipid syndrome. / Raschi, E.; Testoni, C.; Borghi, M. O.; Fineschi, S.; Meroni, P. L.

In: Biomedicine and Pharmacotherapy, Vol. 57, No. 7, 01.09.2003, p. 282-286.

Research output: Contribution to journalArticle

@article{c1bd9c5db56547279b519c65672cb95b,
title = "Endothelium activation in the anti-phospholipid syndrome",
abstract = "Anti-phospholipid syndrome is an autoimmune systemic disease characterized by the persistent presence of anti-phospholipid antibodies and by the occurrence of thrombosis, fetal loss and thrombocytopenia. Anti-phospholipid antibodies are widely accepted as pathogenic antibodies mainly directed against the phospholipid-binding protein beta 2 glycoprotein I. Beta 2 glycoprotein I can be expressed on the endothelial cell membranes of different anatomical localizations and recognized by the autoantibodies. The antibody binding might induce an endothelial activation both in vitro and in vivo experimental models, that was suggested to represent one of the pathogenic mechanisms leading to the prothrombotic state of the syndrome. Beta 2 glycoprotein I endothelial adhesion was found to take place through the interaction of the cationic phospholipid binding site of the molecule with anionic endothelial structures and through annexin II, the endothelial cell receptor for tissue plasminogen activator. Anti-beta 2 glycoprotein I antibodies can directly activate the cells via NF-kB translocation and the signaling cascade triggered by toll like receptors. It has been suggested that beta 2 glycoprotein I might be associated with toll like receptors because of its molecular mimicry with bacterial structures, the natural ligands of toll like receptors. The binding of the antibodies is thought to cross-link beta 2 glycoprotein I and the toll like receptors, eventually switching their signaling pathway.",
keywords = "Anti-phospholipid antibodies, Endothelial cells, Toll like receptors",
author = "E. Raschi and C. Testoni and Borghi, {M. O.} and S. Fineschi and Meroni, {P. L.}",
year = "2003",
month = "9",
day = "1",
doi = "10.1016/S0753-3322(03)00083-0",
language = "English",
volume = "57",
pages = "282--286",
journal = "Biomedicine and Pharmacotherapy",
issn = "0753-3322",
publisher = "Elsevier Masson SAS",
number = "7",

}

TY - JOUR

T1 - Endothelium activation in the anti-phospholipid syndrome

AU - Raschi, E.

AU - Testoni, C.

AU - Borghi, M. O.

AU - Fineschi, S.

AU - Meroni, P. L.

PY - 2003/9/1

Y1 - 2003/9/1

N2 - Anti-phospholipid syndrome is an autoimmune systemic disease characterized by the persistent presence of anti-phospholipid antibodies and by the occurrence of thrombosis, fetal loss and thrombocytopenia. Anti-phospholipid antibodies are widely accepted as pathogenic antibodies mainly directed against the phospholipid-binding protein beta 2 glycoprotein I. Beta 2 glycoprotein I can be expressed on the endothelial cell membranes of different anatomical localizations and recognized by the autoantibodies. The antibody binding might induce an endothelial activation both in vitro and in vivo experimental models, that was suggested to represent one of the pathogenic mechanisms leading to the prothrombotic state of the syndrome. Beta 2 glycoprotein I endothelial adhesion was found to take place through the interaction of the cationic phospholipid binding site of the molecule with anionic endothelial structures and through annexin II, the endothelial cell receptor for tissue plasminogen activator. Anti-beta 2 glycoprotein I antibodies can directly activate the cells via NF-kB translocation and the signaling cascade triggered by toll like receptors. It has been suggested that beta 2 glycoprotein I might be associated with toll like receptors because of its molecular mimicry with bacterial structures, the natural ligands of toll like receptors. The binding of the antibodies is thought to cross-link beta 2 glycoprotein I and the toll like receptors, eventually switching their signaling pathway.

AB - Anti-phospholipid syndrome is an autoimmune systemic disease characterized by the persistent presence of anti-phospholipid antibodies and by the occurrence of thrombosis, fetal loss and thrombocytopenia. Anti-phospholipid antibodies are widely accepted as pathogenic antibodies mainly directed against the phospholipid-binding protein beta 2 glycoprotein I. Beta 2 glycoprotein I can be expressed on the endothelial cell membranes of different anatomical localizations and recognized by the autoantibodies. The antibody binding might induce an endothelial activation both in vitro and in vivo experimental models, that was suggested to represent one of the pathogenic mechanisms leading to the prothrombotic state of the syndrome. Beta 2 glycoprotein I endothelial adhesion was found to take place through the interaction of the cationic phospholipid binding site of the molecule with anionic endothelial structures and through annexin II, the endothelial cell receptor for tissue plasminogen activator. Anti-beta 2 glycoprotein I antibodies can directly activate the cells via NF-kB translocation and the signaling cascade triggered by toll like receptors. It has been suggested that beta 2 glycoprotein I might be associated with toll like receptors because of its molecular mimicry with bacterial structures, the natural ligands of toll like receptors. The binding of the antibodies is thought to cross-link beta 2 glycoprotein I and the toll like receptors, eventually switching their signaling pathway.

KW - Anti-phospholipid antibodies

KW - Endothelial cells

KW - Toll like receptors

UR - http://www.scopus.com/inward/record.url?scp=0141448870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141448870&partnerID=8YFLogxK

U2 - 10.1016/S0753-3322(03)00083-0

DO - 10.1016/S0753-3322(03)00083-0

M3 - Article

VL - 57

SP - 282

EP - 286

JO - Biomedicine and Pharmacotherapy

JF - Biomedicine and Pharmacotherapy

SN - 0753-3322

IS - 7

ER -